

health⁴⁵

The health 45
investment opportunity



health 45: Transforming Wellness Through Investment

Health 45 is an investment opportunity targeting one of the most pressing global health challenges: obesity and related chronic conditions.

Health 45 has identified an exceptional opportunity to bridge this widening gap and address the growing health crisis by investing in innovative businesses poised to make a significant impact on weight-loss and wellness markets.

Two Initial Opportunities:

Envigore: Revolutionising access to effective weight-loss treatments, directly addressing the unfulfilled needs of millions left behind by public healthcare systems.

Reakiro: Leading European manufacturer of scalable, high-quality wellness products that enhance long-term health outcomes, reducing the burden of chronic illnesses.

These businesses are uniquely positioned to capitalise on seismic shifts in the health and wellness landscape. The health 45 investment opportunity offers investors a chance to support these transformative efforts while unlocking significant financial returns

Health45 presents a unique investment opportunity in the growing healthcare and wellness sector. Investors can participate through:

Secured Loan Note (SLN)
Limited Partnership (LP)
Investment Bond.




A Growing Health Crisis and Unmet Demand

63% of UK adults are classified as overweight or obese

(Source: NHS/WHO). Public healthcare systems are underfunded and overburdened, leaving millions without timely access to effective treatments.

Breakthrough weight-loss medications (e.g., Wegovy, Mounjaro) show remarkable results with minimal side effects, tackling obesity-related conditions like diabetes, heart disease, and hypertension.

The demand for these treatments has surged, but supply constraints in both the NHS and private clinics **leave millions underserved.**



Source: NHS – Health Survey for England
Survey figure: 34 million people.

Untapped Demand for Weight-Loss Solutions

Untapped Potential: The NHS plans to treat only 255,000 patients over the next three years, leaving over 3.85 million adults with a BMI >35 without adequate public options.

Expanding Market: When the BMI threshold is lowered from 35 to 30, the potential market expands to 15 million individuals. Lowering it further to BMI >25 raises this figure to 28 million, highlighting a large segment of the adult population in need of effective weight-loss interventions.

Private Sector Demand: Private clinics continue to face long waitlists, reflecting the massive unmet demand that innovative e-pharmacies can address.



Two-Pronged Approach to the Wellness and Weight-Loss Market

Health 45 invests in forward-looking healthcare solutions that address obesity, wellness, and underserved healthcare segments. Two key ventures:

Envigore

Revolutionising access to effective weight-loss treatments, aiming to serve the millions left behind by public healthcare constraints.

Poised to become the UK's leading e-pharmacy and wellness store with best-in-class compliance, telemedicine, and product offerings.

Reakiro




A globally recognised leading manufacturer in CBD and nutraceuticals, operating in 15 countries with a portfolio of 90+ wellness products.

Offers high-margin solutions like CBD oils, mushroom-based remedies, and menopause-targeted treatments, strengthening overall wellness solutions for chronic issues.



A Market Poised for Rapid Growth

- Unprecedented Demand
- NHS trials are consistently oversubscribed; private clinics have extensive waitlists.
- Holistic Benefits
- Modern weight-loss medications reduce chronic disease risks, improving patients' quality of life beyond mere aesthetics
- Cultural Shift
- High-profile media coverage and celebrity endorsements accelerate mainstream adoption.
- Key Takeaway: Envigore stands at this intersection - ready to deliver trusted, effective treatments to a massively underserved population, while Reakiro provides complementary wellness offerings to ensure long-term customer retention.



Empowering Health Through Accessibility

Envigore aims to become the UK's premier e-pharmacy, offering best-in-class weight-loss and **wellness solutions** to UK and European customers.

Initial Focus: Breakthrough weight-loss medications like Wegovy and Mounjaro, tapping into explosive **market demand**.

Future Expansion: Menopause treatments, vitamin B-12 supplementation, and **natural** pain management and anxiety relief.

Compliance and Quality: Partnership with Right Medicine Pharmacy ensures **regulatory adherence**, delivering reliable solutions to underserved markets.

Synergy with Reakiro: Through integrated wellness offerings and telemedicine, Envigore increases customer lifetime value and positions itself as a **trusted partner** in health transformation.



COMPLETE WEIGHT LOSS SOLUTION

- ✓ Clinically Approved
- ✓ Fast Delivery
- ✓ Personalized Plans
- ✓ Post-Sale Support



Claim Your Exclusive Offer:
25%
Lifetime Discount!

Capturing a Fraction of a Vast Market


Projected patient numbers reflect a **cautious** approach, yet highlight the **immense potential** of this market. With a median cost of £2,400 per patient for these life-changing treatments, the **financial returns** align with significant **health benefits**.

Year 1: 3,661 patients
0.089% of BMI > 35 adults
0.024% of BMI > 30 adults
0.012% of BMI > 25 adults

Year 2: 5,227 patients
0.127% of BMI > 35 adults
0.035% of BMI > 30 adults
0.018% of BMI > 25 adults

Year 3: 6,529 patients
0.159% of BMI > 35 adults
0.044% of BMI > 30 adults
0.023% of BMI > 25 adults

Year 4: 8,097 patients
0.197% of BMI > 35 adults
0.054% of BMI > 30 adults
0.029% of BMI > 25 adults



Introduction to Reakiro

Award-Winning Leadership and a Strategic Complement

Global Footprint: Reakiro operates in 15 countries, offering 90+ wellness products.

Proven Success: Top-selling CBD and nutraceutical brand, manufactured in Europe and distributed worldwide. Recognised for quality and innovation with multiple industry awards. Reakiro produce under their own brands and third-party brands.


Why This Matters for health 45:

Reakiro's expertise in product innovation and established brand presence aligns seamlessly with Envigore's e-pharmacy model - together forming a holistic ecosystem for weight loss, pain management, and overall wellness.

By uniting Envigore's clinically proven weight-loss solutions with Reakiro's premium nutraceutical range, patients receive a uniquely tailored and **continuous pathway to better health**. Rather than focusing solely on short-term weight reduction, this partnership guides individuals through ongoing support - from initial prescription to **long-term wellness**. In turn, patients enjoy a holistic, personalised experience that addresses their evolving needs, ultimately fostering greater retention, improved outcomes, and a **singular advantage** in a crowded market.



cannabis trades
association



Beyond Weight Loss: Addressing Broader Health Challenges

Joint & Muscle Pain Management: Natural relief promotes mobility and recovery.

Anxiety Relief: Nutraceutical formulas and CBD oils can reduce stress, enhance mental clarity.

Sleep Disorders: Targeted solutions improve sleep quality—one of the most common health concerns.

Partnering with Envigore: This collaboration ensures **long-term customer retention** with evolving wellness offerings. Together, they bridge immediate weight-loss needs and **sustained, holistic care.**



Innovation Driving Retention and Growth

Digital Infrastructure:

Strategic D2C expansions allow direct access to consumers, fueling growth and retention.

Global Reach:

Partnerships across 15+ countries ensure broad market exposure.

Continuous Product Innovation:

High-margin wellness categories (CBD, nutraceuticals, mushrooms) open new revenue streams.

Long-Term Synergy:


Envigore and Reakiro form a robust ecosystem, bridging immediate clinical needs (weight loss) with ongoing wellness support. This synergy maximises customer lifetime value and brand loyalty.



Health 45 – The Gateway to a Growing Industry

Health 45 invests in dynamic, diversified, and complementary health and wellness brands. By fusing substantial growth potential with proven stability, this investment opportunity empowers investors to embark on a transformative journey across some of the most promising sectors in health and wellness.


Health 45 not only addresses critical market gaps but also unlocks compelling financial rewards. Through focused investments in high-growth ventures like Envigore and Reakiro, investors can anticipate robust returns driven by undeniable market demand and demonstrated operational excellence. This is more than an investment—it's your invitation to shape the future of health and wellness.



Investment Routes

At **Health 45**, we recognise that different investors have different needs.

That's why we offer three distinct ways to participate - through a Limited Partnership, a Secured Loan Note, or an Investment Opportunity. As illustrated, each option flows into Cairngorm Vitality Limited.





www.healthfortyfive.com

This presentation is for informational purposes only and does not constitute an offer to sell or a solicitation to buy any investment or security. The information contained herein is intended solely for individuals who qualify as High Net Worth Individuals or Sophisticated Investors under applicable regulations, and must not be used or relied upon by any person who does not meet these criteria. This document is not intended for distribution to the general public or any investor who is not a relevant person. The contents of this pitch deck do not constitute financial, legal, or tax advice, and potential investors should seek independent advice from their financial advisor, legal counsel, and tax consultant before making any investment decision. Investments of this nature carry significant risks, including the possible loss of the entire investment. Any investment opportunity described will only be available to, and transactions will only be made with, relevant persons as defined by applicable regulations. Persons outside of those categories should not act on the information in this document and have no access to invest based on it.